CTLA4 and neuroblastoma: PBNP reduced the tumor burden and enhanced the immune response, specifically, it increased intrusion of lymphocytes and T cells to the tumor site, which was complemented by the anticancer effects of anti-CTLA-4 immunotherapy, providing a more lasting treatment against neuroblastoma in in vivo experiments.